著者

Yuan Guan Han Zhu Tangkai Qi Renfang Zhang Jun Chen Li Liu Yinzhong Shen Hongzhou Lu Qi Tang

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01437, (Released:2021-11-04)

参考文献数

26

被引用文献数

3

---

In the context of an aging global population, the aging of patients with HIV is an issue that society will have to face. Data indicate that between 2011 and 2019, the proportion of patients age 60 and over who were newly diagnosed with HIV in China increased from 12% to 25%. In contrast to younger groups, the special characteristics of older patients pose major challenges to the management of their disease. The current study examined the clinical outcomes and psychological status of patients age 50 and over who were diagnosed with HIV. Out of a total of 566 older patients from eastern China, viral suppression was achieved in 446 (78.8%), treatment was immunologically effective in 410 (72.4%), and treatment was effective in 324 (57.2%). Thirty-nine patients (6.9%) had significant anxiety and 143 (25.3%) exhibited depressive tendencies. Level of education and the time from diagnosis to treatment were associated with the effectiveness of treatment. Age, sleep quality, chronic illness, exercise, and travel time to medical appointments were associated with depressive symptoms. These findings suggest that the burden of HIV among the older population remains high in more economically developed areas. The urgent need for HIV education and screening programs, as well as follow-up visits and early initiation of treatment in older patients, is called for.

著者

Shuwei Gong Jianxiong Ma Aixian Tian Shuang Lang Zhiheng Luo Xinlong Ma

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01357, (Released:2021-11-04)

参考文献数

100

被引用文献数

2

---

Due to continuous bone remodeling, the bone tissue is dynamic and constantly being updated. Bone remodeling is precisely regulated by the balance between osteoblast-induced bone formation and osteoclast-induced bone resorption. As a giant multinucleated cell, formation and activities of osteoclasts are regulated by macrophage colony-stimulating factor (M-CSF), receptor activator of nuclear factor-kappaB ligand (RANKL), and by pathological destabilization of the extracellular microenvironment. Microenvironmental acidosis, as the prime candidate, is a driving force of multiple biological activities of osteoclast precursor and osteoclasts. The mechanisms involved in these processes, especially acid-sensitive receptors/channels, are of great precision and complicated. Recently, remarkable progress has been achieved in the field of acid-sensitive mechanisms of osteoclasts. It is important to elucidate the relationship between microenvironmental acidosis and excessive osteoclasts activity, which will help in understanding the pathophysiology of diseases that are associated with excess bone resorption. This review summarizes physiological consequences and in particular, potential mechanisms of osteoclast precursor or osteoclasts in the context of acidosis microenvironments.

著者

Youyao Xu Yizhen Chen Fang Han Jia Wu Yuhua Zhang

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01459, (Released:2021-11-10)

参考文献数

58

被引用文献数

6

---

The effectiveness of neoadjuvant therapy (NAT) remains controversial in the treatment of pancreatic cancer (PC). Therefore, this meta-analysis aimed to investigate the clinical differences between NAT and upfront surgery (US) in resectable pancreatic cancer (RPC). Eligible studies were retrieved from PubMed, Embase, and Cochrane Library. The endpoints assessed were R0 resection rate, pathological T stage < 2 rate, positive lymph node rate, and overall survival. A total of 4,588 potentially relevant studies were identified, and 13 studies were included in this study. In patients with RPC, this meta-analysis showed that NAT presented an increased R0 resection rate, pathological T stage < 2 rate, and a remarkably reduced positive lymph node rate compared to US. However, patients receiving NAT did not result in a significantly increased overall survival. These findings supported the application of NAT, especially as a patient selection strategy, in the management of RPC. Additional large clinical studies are needed to determine whether NAT is superior to US.

著者

Siwei Zhang Jing Zhou Lijuan Li Xinyao Pan Jing Lin Chuyu Li Wing Ting Leung Ling Wang

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01320, (Released:2021-11-10)

参考文献数

122

被引用文献数

4

---

In China, cardiovascular disease (CVD) has surpassed malignant tumours to become the disease with the highest mortality rate, and atherosclerosis (AS) is an important pathological cause of CVD. Dehydroepiandrosterone (DHEA) is the most abundant steroid hormone in circulating human blood and is a precursor of estrogen and androgen. DHEA is converted into a series of sex hormones in local peripheral tissues where its acts physiologically. DHEA also acts therapeutically, thereby avoiding the adverse systemic reactions to sex hormones. DHEA inhibits AS, thus inhibiting the development of CVD, and it improves the prognosis for CVD. The incidence of CVD in postmenopausal women is substantially higher than that in premenopausal women, and that incidence is believed to be related to a decrease in ovarian function. The current review analyzes the mechanisms of postmenopausal women's susceptibility to AS. They tend to have dyslipidemia, and their vascular smooth muscle cells (VSMCs) proliferate and migrate more. In addition, oxidative stress and the inflammatory response of endothelial cells (ECs) are more serious in postmenopausal women. This review also discusses how DHEA combats AS by countering these mechanisms, which include regulating the blood lipid status, protecting ECs (including coping with oxidative stress and inflammatory reactions of the vascular endothelium, inhibiting apoptosis of ECs, and inducing NO production) and inhibiting the proliferation and migration of VSMCs. As a result, DHEA has great value in preventing AS and inhibiting its progression in postmenopausal women.

著者

Yang Li Ang Lv Jianhui Wu Chengpeng Li Bonan Liu Xiuyun Tian Hui Qiu Chunyi Hao

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01421, (Released:2021-11-26)

参考文献数

29

被引用文献数

1

---

The occurrence of peritoneal sarcomatosis (PS) in patients with retroperitoneal sarcoma (RPS) indicates a poor prognosis. However, the appropriate treatment modality remains unclear. This study aimed to identify its prognostic factors and further explore the role of macroscopically complete excision (CE) in the management of PS. A retrospective database was established to evaluate patients with RPS who underwent resection between January 2011 and January 2019. Univariate and multivariate survival analyses were performed to analyze the prognostic factors and identify the population that will optimally benefit from CE. This study included a total of 49 patients with PS from 211 patients with RPS, and 34 (69.4%) patients of whom with PS underwent CE successfully. The median follow-up time was 36.0 months. There were 8 patients excluded because of loss to follow-up (n = 4) or death from complications within 90 days postoperatively (n = 4). The CE group had a marginally better prognosis compared to the macroscopically incomplete excision (IE) group (median disease-specific survival: 20 months vs. 8 months). Multivariate survival analysis demonstrated that completeness of operation (CE vs. IE) was the only independent prognostic factor in PS patients (P = 0.042). There was no significant difference in the overall complications between the CE and IE groups (P = 0.205). In conclusion, completeness of macroscopical excision is an independent prognostic predictor of PS. If technically possible, CE is a feasible strategy to improve the prognosis of selected patients with PS.

著者

Dawei Lin Chen Wu Yiwen Jiang Yigang Li Xi Zhang Yaosheng Wang

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01461, (Released:2021-12-04)

参考文献数

20

被引用文献数

2

---

It remains unknown whether and to what extend the angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) can play a role in the development of atrial fibrillation (AF) after pacemaker implantation in very old patients. Therefore, we aimed to investigate the association between oral ACEIs or ARBs and the risk of developing AF in very old patients after pacemaker implantation. Patients above 80 years old with pacemaker implantation and without baseline history of AF were included and their real-world information about ACEIs or ARBs use was extracted from electronic medical records. New AF cases were confirmed via the records of outpatient visits. The multivariable Cox proportional-hazards model was used to evaluate the associations between oral ACEIs or ARBs and risk of AF after pacemaker implantation. Among a total of 388 identified patients aged 80 to 98 years, 118 used ACEIs, 174 had ARBs therapy, and 115 AF were identified after pacemaker implantation during a median follow-up time of 3.1 years. After adjustment for potential confounders, patients with daily use of ARBs had a relatively lower risk of AF after pacemaker implantation (HR: 0.627, 95% CI: 0.425, 0.926; P = 0.019) compared with those non-users, whereas ACEIs therapy didn't show a significant relation with AF risk (HR: 1.335, 95% CI: 0.894, 1.995; P = 0.157). In conclusion, for very old patients with a permanent pacemaker, daily use of oral ARBs was associated with a relative lower risk of AF after pacemaker implantation, however, daily use of ACEIs was not related with AF risk.

著者

Wei Zhang Yingying Wang Xiang Dong Bo Yang Hongyuan Zhou Lu Chen Zewu Zhang Qin Zhang Guangtai Cao Zhiqiang Han Huikai Li Yunlong Cui Qiang Wu Ti Zhang Tianqiang Song Qiang Li

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01517, (Released:2021-12-09)

参考文献数

38

被引用文献数

10

---

We explored the prognostic value of preoperative CA19-9 in α-fetoprotein (AFP)-positive and -negative HCC with hepatitis B virus (HBV) background (HBV-HCC), and explored the underlying mechanism. Recurrence-free survival (RFS) and overall survival (OS) were assessed in HBV-HCC patients who underwent curative resection (Cohort 1). Immunohistochemical staining of CA19-9 in HCC and liver parenchyma were quantified in another cohort of 216 patients with resected HCC (Cohort 2). Immunohistochemical staining of CA19-9 and serum CA19-9 level was also compared between patients with HCC and intrahepatic cholangiocarcinoma (ICC) (Cohort 3). In Cohort 1, CA19-9 ≥ 39 U/mL was an independent risk factor for RFS (HR = 1.507, 95% CI = 1.087-2.091, p = 0.014) and OS (HR = 1.646, 95% CI = 1.146-2.366, p = 0.007). CA19-9 ≥ 39 U/mL was also associated with significantly higher incidence of macrovascular invasion (MaVI) compared with CA19-9 < 39 U/mL (23.0% vs. 7.2%, p = 0.002), and elevated aminotransferase and aspartate aminotransferase to platelet ratio index (APRI), and lower albumin. Immunohistochemical staining of CA19-9 revealed that CA19-9 expression was found exclusively in the background liver but not in HCC tumor cells. In contrast, tumor tissue was the main source of CA19-9 in ICC patients. CA19-9 ≥ 39 U/mL was associated with worse OS and RFS in both AFP-positive and negative HCC patients. CA19-9 indicated more severe inflammation and cirrhosis in the liver of HCC patients.

著者

Yun He Hongzhou Lu

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01514, (Released:2021-12-08)

参考文献数

11

被引用文献数

3

---

Since the first edition of the guidelines for the diagnosis and treatment of AIDS was published in 2005, the AIDS Specialists Group of the Society of Infectious Diseases has updated the guidelines three more times to include more thorough, practical, standardized, and specific content. The latest edition (the 2021 version) has recently been updated in China in accordance with clinical practice nationwide and results of the latest research. Compared to the four previous editions, the 2021 edition references the latest information on the epidemiology of HIV, the prevention of HIV transmission, standardized lab diagnosis, and clinical management. First, the guidelines highlight the concept of "enhancing the combination of early intervention, prevention, and treatment". The guidelines specify more detailed clinical phases (three clinical stages), the clinical staging and progression of AIDS, and patient prognosis. The guidelines also specify diagnostic criteria – HIV antibodies, HIV RNA tests, CD4 cell counts, and the patient's epidemiological history – to use in conjunction with symptoms to confirm an HIV infection. In addition, the guidelines summarize more advanced HIV/AIDS research in China by describing the different circulating recombinant forms (CRFs) and unique recombinant forms (URFs) in Chinese patients, by summarizing the most prevalent strains in the Chinese population, and by comparing disease progression by route of transmission and by the CD4+T cell count. Lastly, this edition describes ways to optimize programs to prevent mother-to-child transmission, strategies for diagnosis and treatment of opportunistic infections, the aging patient population, and specialized ART treatment programs for different populations living with HIV. The guidelines should not only help to prolong the life of people living with HIV and improve their quality of life but also encourage successful collaboration between scientific researchers and physicians in the area of HIV.

著者

Xiaorong Wang Huimin Huang Yiyi Zhu Shaoli Li Peifen Zhang Jiajun Jiang Caixi Xi Lingling Wu Xingle Gao Yaoyang Fu Danhua Zhang Yiqing Chen Shaohua Hu Jianbo Lai

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01317, (Released:2021-09-30)

参考文献数

60

被引用文献数

3

---

Antipsychotic-induced metabolic dysfunction (AIMD) is an intractable clinical challenge worldwide. The situation is becoming more critical as second-generation antipsychotics (SGAs), to a great extent, have replaced the role of first-generation antipsychotics in managing major psychiatric disorders. Although the exact mechanisms for developing AIMD is intricate, emerging evidence has indicated the involvement of the microbiota-gut-brain axis in AIMD. SGAs treatment may change the diversity and compositions of intestinal flora (e.g., decreased abundance of Bacteroidetes and Akkermansia muciniphila, and increased Firmicutes). Short-chain fatty acids and other metabolites derived from gut microbiota, on the one hand, can regulate the activity of intestinal endocrine cells and their secretion of satiety hormones (e.g., glucagon-like peptide 1, peptide YY, cholecystokinin and ghrelin); on the other hand, can activate the vagus nerve or transport into the brain to exert a central modulation of foraging behaviors via binding to neuropeptide receptors. Interestingly, metformin, a classical antidiabetic agent, is capable of alleviating AIMD possibly by regulating the microbiota-gut-brain axis. That is, metformin can not only partially reverse the alterations of gut microbial communities due to SGAs treatment, but also play a positive role in rectifying the disturbances of peripheral and central satiety-related neuropeptides. Current evidence has indicated a promising role for metformin on ameliorating AMID, but further verifications in well-designed clinical trials are still warranted.

著者

Bo Tian Jianjun Sun Jinsong Bai Renfang Zhang Jun Liu Yinzhong Shen Chongxi Li Li Liu Jun Chen Tangkai Qi Hongzhou Lu

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01279, (Released:2021-09-29)

参考文献数

31

---

Both cytomegalovirus (CMV) viremia and disseminated nontuberculous mycobacterial (NTM) disease are common opportunistic infections in AIDS patients. Whether concurrent CMV viremia is associated with mortality in patients with AIDS and disseminated NTM disease is unknown. Subjects were patients with AIDS and disseminated NTM disease seen at a single center from January 2015 to April 2021. Data were retrospectively collected. Differences in demographics and clinical characteristics and hospitalization survival rates were compared between patients with disseminated NTM and with CMV viremia or not. Subjects were 113 AIDS patients with disseminated NTM who were seen at this Hospital from January 2015 to April 2021. Twenty-six of the patients had CMV viremia and 87 did not. The median age was 36 years (interquartile range [IQR] 29-42) and 108 patients were male (96%). The median CD4 count was 7 cells/µL (IQR 3-17). The median plasma CMV viral load was 9,245 IU/mL (IQR 3147-45725). The serum albumin of patients with CMV viremia was significantly lower than that of patients without CMV viremia (P = 0.03). Compared to patients without CMV viremia (81.6%), patients with CMV viremia had a significantly poorer prognosis (P = 0.01). Cox regression analysis indicated that the risk of a poor prognosis in patients with CMV viremia was 4.7 times higher than that in patients without CMV viremia (P = 0.003), and patients with CD8 more than 250/μL had a better prognosis (P = 0.02). CMV viremia increases the risk of a poor prognosis in patients with AIDS and a disseminated NTM infection. A routine CMV DNA test should be performed on patients with AIDS and disseminated NTM disease in order to reduce the risk of death.

著者

Luyan Shen Lixiang Wang Cong Liu Shaomin Shi Tai Takahashi Tiejun Wang

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01342, (Released:2021-09-03)

参考文献数

94

被引用文献数

3

---

Community-acquired pneumonia (CAP) refers to infectious inflammation of the lung parenchyma developing outside of a hospital. CAP has quite a high mortality and morbidity rate worldwide, and especially among elderly patients. The increasing burden of CAP is due to antibiotic resistance, the growth of the elderly population, and underlying comorbidities. Streptococcus pneumoniae remains the most common bacterial pathogen causing CAP, but multi-drug resistance bacteria and potential pathogens have increased the difficulty and challenges of managing CAP. Although preventive measures, diagnostic techniques, and treatment strategies are constantly advancing and improving, the susceptibility of multi-drug resistant pathogens, such as including Methicillin-Resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae, and Pseudomonas aeruginosa, has not improved significantly in recent decades, thus highlighting the importance and necessity of developing new antibiotics for the treatment of CAP. New antimicrobials have been approved over the past few years that will expand treatment options for CAP, and especially for patients with potential comorbidities. This situation also offers the chance to reduce the abuse of antibiotics, their toxicities, and their adverse reactions and to provide effective personalized antibiotic treatment.

著者

Qian Li Xiangming Zhan Jun Wang Hongzhou Lu

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01361, (Released:2021-08-30)

参考文献数

16

被引用文献数

6

---

Induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants, the COVID-19 pandemic has caused a serious crisis for healthcare systems worldwide. COVID-19 vaccine coverage has increased in many countries, but the COVID-19 epidemic has rapidly expanded, with a daily increase of 30,390 COVID-19 cases and 9,761 deaths since August 12, 2021. This article provides a brief overview of growing concerns about a rebound of the COVID-19 pandemic caused by the Delta variant and public health epidemic control measures that have recently been relaxed. As of August 13, 2021, 465,679 cases of COVID-19 due to the Delta variant of SARS-CoV-2 have been detected in over 120 countries. Epidemic control measures were relaxed in some areas, such as allowing large gatherings and improper criteria for ending self-isolation. Even in China, where the epidemic was tightly controlled with strict non-pharmaceutical interventions (NPIs), new COVID-19 cases, and asymptomatic cases in particular, spiked in the first 13 days of August. More importantly, most of those cases were local, while most of the cases accounting for the previous increase were imported. Therefore, relaxed epidemic control measures and asymptomatic infections possibly caused by the Delta variant of SARS-CoV-2 may increase the risk of virus transmission. Accordingly, suggestions for COVID-19 containment, such as encouraging vaccination of the general population, using Internet of Things technology (loT) to reduce the possibility of contact with the asymptomatic infected, and enhancing disease surveillance, have been offered here.

著者

Yueming Shao Jun Chen Hongzhou Lu

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01346, (Released:2021-08-25)

参考文献数

39

被引用文献数

5

---

Coronavirus disease 19 (COVID-19) continues to rage as a global pandemic. A number of potential therapeutic agents have been explored over the past year or two. However, numerous drugs that were expected to prove highly effective, such as lopinavir/ritonavir and remdesivir, have been found to have little benefit in large clinical trials. Interleukin-6 receptor antagonists, glucocorticoids, Janus kinase inhibitors, and some antivirals have been found to provide significant benefits in terms of reducing viral load, reducing the time of nucleic acid conversion, or improving survival. For example, bamlanivimab and etesevimab, which are newly designed monoclonal antibodies against the surface spike protein S1 subunit receptor-binding domain (RBD) of SARS-CoV-2, have a significant effect on reducing the viral load and the hospitalization rate of patients with mild COVID-19. Several vaccines against SARS-CoV-2 have been widely administered worldwide and have provided good protection. Nevertheless, the increasingly hardy variants of the virus have raised the requirements for vaccine design. Perhaps RBD-based vaccines are a viable way to defend against variants, but this still needs to be verified in a large sample. Therefore, this paper provides an update on the treatment options for COVID-19 based on three previously proposed dimensions of drug screening: standard assays of existing broad-spectrum antivirals, screening of chemical libraries, and redevelopment of new, specific drugs.

著者

Xiaoyi Zhang Hua Qiu Chensheng Li Pingping Cai Fanghua Qi

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01318, (Released:2021-08-20)

参考文献数

84

被引用文献数

81

---

Traditional Chinese medicine (TCM), especially Chinese herbal medicines and acupuncture, has been traditionally used to treat patients with cancers in China and other East Asian countries. Numerous studies have indicated that TCM not only alleviates the symptoms (e.g., fatigue, chronic pain, anorexia/cachexia, and insomnia) of patients with cancer and improves their quality of life (QOL) but also diminishes adverse reactions and complications caused by chemotherapy, radiotherapy, or targeted-therapy. Therefore, Chinese herbal medicines and acupuncture and other alternative therapies need to be understood by TCM physicians and other health care providers. This review mainly summarizes the experimental results and conclusions from literature published since 2010, and a search of the literature as been performed in the PubMed, MEDLINE, Web of Science, Scopus, Springer, ScienceDirect, and China Hospital Knowledge Database (CHKD) databases. Some Chinese herbal medicines (e.g., Panax ginseng, Panax quinquefolius, Astragali radix, Bu-zhong-yi-qi-tang (TJ-41), Liu-jun-zi-tang (TJ-43), Shi-quan-da-bu-tang (TJ-48), and Ban-xia-xie-xin-tang (TJ-14)) and some acupuncture points (e.g., Zusanli (ST36), Zhongwan (CV12), Neiguan (PC6) and Baihui (GV20)) that are commonly used to treat cancer-related symptoms and/or to reduce the toxicity of chemotherapy, radiotherapy, or targeted-therapy are highlighted and summarized. Through a review of literature, we conclude that TCM can effectively alleviate adverse gastrointestinal reactions (including diarrhea, nausea, and vomiting) to these anti-cancer therapies, decrease the incidence of bone marrow suppression, alleviate cardiotoxicity, and protect against chemotherapy-induced peripheral neuropathy and radiation-induced pneumonitis. Moreover, TCM can alleviate epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)-related acneiform eruptions, diarrhea, and other adverse reactions. The hope is that this review can contribute to an understanding of TCM as an adjuvant therapy for cancer and that it can provide useful information for the development of more effective anti-cancer therapies. However, more rigorously designed trials involving cancer treatment must be conducted in the future, including complete quality control and standardized models at the cellular, organic, animal and clinical levels, in order to study TCM in multiple forms and at multiple levels.

著者

Yanmin Du Jianlu Zhang Guanyang Chen Zhipeng Sun

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01287, (Released:2021-07-30)

参考文献数

26

被引用文献数

8

---

Obesity and related metabolic diseases have become one of the world's most serious public health problems. Bariatric surgery has gone through a long and difficult development process, from being rejected to gradually recognized, then widely accepted, and finally becoming the "gold standard" for the treatment of morbid obesity with metabolic diseases. Procedures have constantly been improving and evolving as the concept of bariatric surgery has been reappraised. The comparison and selection of different procedures, the emergence of new technologies and treatment methods, and the in-depth study of the mechanism of metabolic weight loss surgery are effectively promoting the rapid development of bariatric surgery. This article looks at both the 2014 and 2019 editions of the Guidelines for Diagnosis and Treatment of Obesity and Type 2 Diabetes Mellitus from the Chinese Society of Metabolic and Bariatric Surgery (CSMBS), its review the development of bariatric surgery, and it describes surgical indications and contraindications, the mechanism of weight loss, and tailored selection of the surgical procedure in order to serve as a reference.

著者

Chen Wu Dawei Lin Fei Ma Feng Jiang Yaosheng Wang

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01278, (Released:2021-07-23)

参考文献数

51

被引用文献数

5

---

Onco-cardiology is an emerging field linking cancer with cardiovascular injury. Understanding the mechanism of cardiac injury helps improve the quality of life of cancer survivors. A series of studies on adverse reactions to cancer or oncological treatments has indicated that adverse cardiovascular events related to cancer treatments may occur over a longer period of survival, and even years after therapy has concluded. Current cancer therapies, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy, have been found to have latent cardiovascular toxicity. These toxic effects are often progressive and irreversible and ultimately lead to cardiovascular events such as heart failure, hypertension, coronary heart diseases, arrhythmia, and thromboembolism. Therefore, more emphasis should be placed on revealing the mechanism of cancer treatment-related cardiovascular toxicity. This would help to guide prevention, diagnosis, and treatment of CVDs in cancer survivors.

著者

Tatsuo Sawakami Kenji Karako Peipei Song Wataru Sugiura Norihiro Kokudo

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01269, (Released:2021-07-13)

参考文献数

26

被引用文献数

10

---

In Japan, the Law Concerning the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases (the "Infectious Diseases Control Law") classifies infectious diseases as category I-V infectious diseases, pandemic influenza, and designated infectious diseases based on their infectivity, severity, and impact on public health. COVID-19 was designated as a designated infectious disease as of February 1, 2020 and then classified under pandemic influenza as of February 13, 2021. According to national reports from sentinel surveillance, some infectious diseases transmitted by droplets, contact, or orally declined during the COVID-19 epidemic in Japan. As of week 22 (June 6, 2021), there were 704 cumulative cases of seasonal influenza, 8,144 cumulative cases of chickenpox, 356 cumulative cases of mycoplasma pneumonia, and 45 cumulative cases of rotavirus gastroenteritis; these numbers were significantly lower than those last year, with 563,487 cumulative cases of seasonal influenza, 31,785 cumulative cases of chickenpox, 3,518 cumulative cases of mycoplasma pneumonia, and 250 cumulative cases of rotavirus gastroenteritis. Similarly, many infectious diseases transmitted by droplets or contact declined in other countries and areas during the COVID-19 pandemic. One can reasonably assume that various measures adopted to control the transmission of COVID-19 have played a role in reducing the spread of other infectious diseases, and especially those transmitted by droplets or contact. Extensive and thorough implementation of personal protective measures and behavioral changes may serve as a valuable reference when identifying ways to reduce the spread of infectious diseases transmitted by droplets or contact in the future.

著者

Hiroshi Okada Mitsuko Onda Masaki Shoji Naoki Sakane Yasushi Nakagawa Takashi Sozu Yui Kitajima Ross T. Tsuyuki Takeo Nakayama

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

vol.11, no.6, pp.632-639, 2017-12-31 (Released:2018-01-09)

参考文献数

30

被引用文献数

13 28

---

The COMmunity Pharamcists ASSist for Blood Pressure (COMPASS-BP) study aimed to assess the effectiveness of lifestyle support programs administered in community pharmacies on hypertension control. This open-label, two-armed parallel group, cluster-randomized controlled trial included 73 pharmacies (clusters) in Japan randomized to a control or intervention group. Eligible hypertensive patients (n = 125), aged 20-75 years, received the intervention (n = 64) or the control treatment (n = 61), as dictated by their pharmacy randomization. Patients in the intervention group received brochures and healthy lifestyle advice from pharmacists using motivational interviewing methods during pharmacy visits over a 12-week period, with their usual pharmacy care. Conversely, the control group just received usual care. The main outcome measure was a change in morning systolic blood pressure (SBP) from baseline to week 12. The intervention group exhibited a decrease in morning SBP that was 6.0 mmHg greater than that of the control group (95% confidence interval [CI]: −11.0 to −0.9, p = 0.021). In a mixed-effect model for repeated measures analysis, the intergroup difference in morning SBP decrease was −4.5 mmHg (95% CI: −8.5 to −0.6, p = 0.024). Our findings indicate that implementation of a lifestyle advice program in pharmacies is feasible and may lead to reduced blood pressure.

著者

Mingyu Luo Jimin Sun Zhenyu Gong Zhen Wang

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01218, (Released:2021-06-16)

参考文献数

19

被引用文献数

6

---

The COVID-19 pandemic continues to ravage the world. As many countries have entered the postpandemic period, current efforts to prevent and control COVID-19 have gradually been normalized in many countries. Although the focus is on vaccines to achieve herd immunity, conventional physical containment strategies should be reassessed as part of efforts to prevent and control infectious diseases. Continued respiratory protective measures such as social distancing and the wearing of masks have been extensively accepted by the public in most countries. A point worth noticing is that the activities of influenza and other respiratory diseases have decreased as these strategies have been implemented. Public mobilization and large-scale campaigns to promote health are also important to interrupting the transmission of pathogens. A good example can be found in the achievements of China's Patriotic Public Health Campaign. These practices underscore the importance of enhancing physical containment strategies and public mobilization and management, with support from the legal system, to respond to any potential emerging infectious diseases.

著者

Qian Li Jun Wang Haiwei Lv Hongzhou Lu

出版者

International Research and Cooperation Association for Bio & Socio-Sciences Advancement

雑誌

BioScience Trends (ISSN:18817815)

巻号頁・発行日

pp.2021.01242, (Released:2021-06-26)

参考文献数

22

被引用文献数

7

---

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a serious public health burden. As the COVID-19 epidemic in China would coincide with a seasonal outbreak of influenza, there were serious concerns about whether influenza would be aggravated by the SARS-CoV-2 infection and COVID-19 pandemic. This article provides a brief overview of the impacts of the COVID-19 epidemic on influenza activity in China. The percentage of positive influenza tests decreased during the COVID-19 pandemic. During the first stage of the COVID-19 outbreak, the percentage of positive influenza tests reached to a peak of 47.7%. At the second stage, the percentage of positive influenza tests was dramatically decreased from 40.4% to 14.0%. Thereafter, it remains at a low level of less than 6.2%. In addition, the possible causes of this phenomenon have been summarized, including prevention and control measures and ecological competition. Lastly, this article suggests that the public health approach to preventing COVID-19 may also help to control other respiratory infectious diseases. Public health measures need to be maintained even in the later stages of the COVID-19 epidemic.